Emerging Risk of Campylobacter spp. Infection Associated with Anti-BCMA and Anti-GPRC5D Bispecific Antibodies
✅ Just Accepted
🔗 https://bit.ly/3LsCGeP
✅ Just Accepted
🔗 https://bit.ly/3LsCGeP
November 9, 2025 at 9:14 PM
Emerging Risk of Campylobacter spp. Infection Associated with Anti-BCMA and Anti-GPRC5D Bispecific Antibodies
✅ Just Accepted
🔗 https://bit.ly/3LsCGeP
✅ Just Accepted
🔗 https://bit.ly/3LsCGeP
Bispecific antibodies targeting BCMA and GPRC5D showed efficacy in 85 refractory multiple myeloma patients. Notably, 9 had Campylobacter infections (5 bloodstream, 5 gastrointestinal). 🦠##idsky
Emerging Risk of Campylobacter spp. Infection Associated with Anti-BCMA and Anti-GPRC5D Bispecific Antibodies
AbstractBispecific antibodies directed against BCMA and GPRC5D have shown remarkable efficacy in patients with refractory multiple myeloma; however, concerns regarding infection risk are emerging. In a cohort of 85 treated patients, we observed a notable incidence of Campylobacter infections, including five bloodstream and five gastrointestinal episodes, affecting nine individuals. This unexpectedly high burden of infection highlights the vulnerability of this immunocompromised population and underscores the urgent need for studies evaluating targeted preventive and surveillance strategies.
academic.oup.com
November 5, 2025 at 1:00 AM
Bispecific antibodies targeting BCMA and GPRC5D showed efficacy in 85 refractory multiple myeloma patients. Notably, 9 had Campylobacter infections (5 bloodstream, 5 gastrointestinal). 🦠##idsky
IASO Bio's Innovative CAR-T Therapy Shows Promise for Multiple Myeloma Patients#China#Shanghai#IASO_Bio#CAR-T#GPRC5D
IASO Bio's Innovative CAR-T Therapy Shows Promise for Multiple Myeloma Patients
IASO Biotherapeutics announces significant results for RD118, its anti-GPRC5D CAR-T therapy, offering hope for multiple myeloma patients with few options left.
third-news.com
October 22, 2025 at 11:45 AM
How should we choose optimal salvage treatments following BCMA-directed CAR-T therapy in multiple myeloma?
Check out our review article out today summarizing recent studies and our approach to therapy sequencing from our team at @ucsfcancer.bsky.social #MMsm #myeloma
dx.doi.org/10.1080/1750...
Check out our review article out today summarizing recent studies and our approach to therapy sequencing from our team at @ucsfcancer.bsky.social #MMsm #myeloma
dx.doi.org/10.1080/1750...
October 18, 2025 at 2:29 AM
How should we choose optimal salvage treatments following BCMA-directed CAR-T therapy in multiple myeloma?
Check out our review article out today summarizing recent studies and our approach to therapy sequencing from our team at @ucsfcancer.bsky.social #MMsm #myeloma
dx.doi.org/10.1080/1750...
Check out our review article out today summarizing recent studies and our approach to therapy sequencing from our team at @ucsfcancer.bsky.social #MMsm #myeloma
dx.doi.org/10.1080/1750...
Thérapie par #CAR_T 🧬 ciblée par #GPRC5D ( #CT071) pour le #MyélomeMultiple 🩸 R/R : 1er essai de phase 1 chez l’homme.
Le taux de réponse est de 100 % (IC à 95 % : 83,2-100), avec une réponse complète ou un taux supérieur de 50 % (dix patients sur 20).
www.thelancet.com/journals/lan...
Le taux de réponse est de 100 % (IC à 95 % : 83,2-100), avec une réponse complète ou un taux supérieur de 50 % (dix patients sur 20).
www.thelancet.com/journals/lan...
GPRC5D-targeted CAR T-cell therapy (CT071) in patients with relapsed or refractory multiple myeloma: a first-in-human, single-centre, single-arm, phase 1 trial
CT071 demonstrated an encouraging safety profile with compelling activity in patients
with relapsed or refractory multiple myeloma.
www.thelancet.com
October 8, 2025 at 3:01 PM
Thérapie par #CAR_T 🧬 ciblée par #GPRC5D ( #CT071) pour le #MyélomeMultiple 🩸 R/R : 1er essai de phase 1 chez l’homme.
Le taux de réponse est de 100 % (IC à 95 % : 83,2-100), avec une réponse complète ou un taux supérieur de 50 % (dix patients sur 20).
www.thelancet.com/journals/lan...
Le taux de réponse est de 100 % (IC à 95 % : 83,2-100), avec une réponse complète ou un taux supérieur de 50 % (dix patients sur 20).
www.thelancet.com/journals/lan...
✨ #CARsgen présente les résultats du #CT071 ( #CAR_T 🧬 autologue ciblant #GPRC5D) pour le traitement du #MyélomeMultiple 🩸 R/R dans le cadre d’un essai initié par l’investigateur ( #NCT05838131) ont été publiés dans "The Lancet Haematology 🩸"
www.prnewswire.com/news-release...
www.prnewswire.com/news-release...
CARsgen Presents Results on GPRC5D CAR-T CT071 in The Lancet Haematology
/PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that...
www.prnewswire.com
October 8, 2025 at 2:57 PM
✨ #CARsgen présente les résultats du #CT071 ( #CAR_T 🧬 autologue ciblant #GPRC5D) pour le traitement du #MyélomeMultiple 🩸 R/R dans le cadre d’un essai initié par l’investigateur ( #NCT05838131) ont été publiés dans "The Lancet Haematology 🩸"
www.prnewswire.com/news-release...
www.prnewswire.com/news-release...
CARsgen Therapeutics Unveils Promising Results for CT071 in Treating Multiple Myeloma#China#Shanghai#CAR-T#CARsgen#GPRC5D
CARsgen Therapeutics Unveils Promising Results for CT071 in Treating Multiple Myeloma
CARsgen Therapeutics has revealed encouraging results for its CT071 CAR T-cell therapy targeting GPRC5D in patients with relapsed/refractory multiple myeloma, documented in The Lancet.
third-news.com
October 8, 2025 at 12:27 AM
The findings provide a systematic approach to accelerate the discovery of GPRC5D-targeted therapeutics, potentially leading to new treatment options for blood cancers like multiple myeloma.
September 21, 2025 at 3:05 AM
The findings provide a systematic approach to accelerate the discovery of GPRC5D-targeted therapeutics, potentially leading to new treatment options for blood cancers like multiple myeloma.
This study developed a multistep computational screening strategy to identify small-molecule inhibitors targeting GPRC5D, a promising target for immunotherapy in hematologic malignancies.
September 21, 2025 at 3:05 AM
This study developed a multistep computational screening strategy to identify small-molecule inhibitors targeting GPRC5D, a promising target for immunotherapy in hematologic malignancies.
Uncover potential GPRC5D inhibitors - a promising target for blood cancer treatment. Rigorous virtual screening and simulations identify 4 top candidates, with compound 2 showing strong b...
🧵 Thread below
Full analysis: https://helixbrief.com/article/f99a9d46-3e0d-468c-b58e-75ee9fceb9e9
🧵 Thread below
Full analysis: https://helixbrief.com/article/f99a9d46-3e0d-468c-b58e-75ee9fceb9e9
September 21, 2025 at 3:05 AM
Uncover potential GPRC5D inhibitors - a promising target for blood cancer treatment. Rigorous virtual screening and simulations identify 4 top candidates, with compound 2 showing strong b...
🧵 Thread below
Full analysis: https://helixbrief.com/article/f99a9d46-3e0d-468c-b58e-75ee9fceb9e9
🧵 Thread below
Full analysis: https://helixbrief.com/article/f99a9d46-3e0d-468c-b58e-75ee9fceb9e9
Coming up at #IMS25: Dr. Sham Mailankody will share the results of a phase 1 clinical trial of concurrent BCMA and GPRC5D #CARTcells for relapsed/refractory #multiplemyeloma.
🗓️ Thursday, September 18 | 4:40 p.m. EDT
@mskcancercenter.bsky.social @szusmani.bsky.social @myeloma-society.bsky.social
🗓️ Thursday, September 18 | 4:40 p.m. EDT
@mskcancercenter.bsky.social @szusmani.bsky.social @myeloma-society.bsky.social
September 18, 2025 at 6:02 PM
Coming up at #IMS25: Dr. Sham Mailankody will share the results of a phase 1 clinical trial of concurrent BCMA and GPRC5D #CARTcells for relapsed/refractory #multiplemyeloma.
🗓️ Thursday, September 18 | 4:40 p.m. EDT
@mskcancercenter.bsky.social @szusmani.bsky.social @myeloma-society.bsky.social
🗓️ Thursday, September 18 | 4:40 p.m. EDT
@mskcancercenter.bsky.social @szusmani.bsky.social @myeloma-society.bsky.social
Paola Neri, MD, PhD, said that baseline screening for BCMA or GPRC5D expression/mutations using genomic-based methods can help individualize myeloma treatments. #IMS25
September 18, 2025 at 3:32 PM
Paola Neri, MD, PhD, said that baseline screening for BCMA or GPRC5D expression/mutations using genomic-based methods can help individualize myeloma treatments. #IMS25
Leads Biolabs Achieves Milestone with First Patient Dosed in LBL-034 Phase Ⅱ Trial#Leads_Biolabs#GPRC5D#LBL-034
Leads Biolabs Achieves Milestone with First Patient Dosed in LBL-034 Phase Ⅱ Trial
Leads Biolabs announces the successful dosing of the first patient in the Phase Ⅱ trial of LBL-034, a bispecific T-cell engager aiming to target GPRC5D in cancer.
third-news.com
August 25, 2025 at 10:27 AM
Leads Biolabs Achieves Milestone with First Patient Dosed in LBL-034 Phase Ⅱ Trial#Leads_Biolabs#GPRC5D#LBL-034
How do you navigate the complexities of GPRC5D-targeted treatment in #MultipleMyeloma? 🩸
Our interactive feature breaks down the value of GPRC5D as a target in #myeloma, mechanisms of resistance, how to manage associated toxicities, & more!
Check it out:
➡️ buff.ly/hlBht3j
#MMSM #ImmunoOnc #HemOnc
Our interactive feature breaks down the value of GPRC5D as a target in #myeloma, mechanisms of resistance, how to manage associated toxicities, & more!
Check it out:
➡️ buff.ly/hlBht3j
#MMSM #ImmunoOnc #HemOnc
August 13, 2025 at 5:05 PM
How do you navigate the complexities of GPRC5D-targeted treatment in #MultipleMyeloma? 🩸
Our interactive feature breaks down the value of GPRC5D as a target in #myeloma, mechanisms of resistance, how to manage associated toxicities, & more!
Check it out:
➡️ buff.ly/hlBht3j
#MMSM #ImmunoOnc #HemOnc
Our interactive feature breaks down the value of GPRC5D as a target in #myeloma, mechanisms of resistance, how to manage associated toxicities, & more!
Check it out:
➡️ buff.ly/hlBht3j
#MMSM #ImmunoOnc #HemOnc
GPRC5D-directed therapies are reshaping the #MultipleMyeloma treatment landscape.🩸
Explore practical considerations with the use of GPRC5D-directed agents in our interactive expert feature. 🔍
Click here:
📖 buff.ly/PKlan0C
#MMsm #Myeloma #CellTherapy #ImmunoOnc #GPRC5D #HemOnc #BloodSky
Explore practical considerations with the use of GPRC5D-directed agents in our interactive expert feature. 🔍
Click here:
📖 buff.ly/PKlan0C
#MMsm #Myeloma #CellTherapy #ImmunoOnc #GPRC5D #HemOnc #BloodSky
August 4, 2025 at 2:02 PM
GPRC5D-directed therapies are reshaping the #MultipleMyeloma treatment landscape.🩸
Explore practical considerations with the use of GPRC5D-directed agents in our interactive expert feature. 🔍
Click here:
📖 buff.ly/PKlan0C
#MMsm #Myeloma #CellTherapy #ImmunoOnc #GPRC5D #HemOnc #BloodSky
Explore practical considerations with the use of GPRC5D-directed agents in our interactive expert feature. 🔍
Click here:
📖 buff.ly/PKlan0C
#MMsm #Myeloma #CellTherapy #ImmunoOnc #GPRC5D #HemOnc #BloodSky
Talquetamab, the first GPRC5D × CD3 bispecific antibody, shows remarkable 66% response rates in relapsed/refractory multiple myeloma patients. Its optimal dosing regimen balances efficacy...
🧵 Thread below
Full analysis: https://helixbrief.com/article/5da86a14-a16c-4685-a82f-995d789f08f5
🧵 Thread below
Full analysis: https://helixbrief.com/article/5da86a14-a16c-4685-a82f-995d789f08f5
August 4, 2025 at 6:46 AM
Talquetamab, the first GPRC5D × CD3 bispecific antibody, shows remarkable 66% response rates in relapsed/refractory multiple myeloma patients. Its optimal dosing regimen balances efficacy...
🧵 Thread below
Full analysis: https://helixbrief.com/article/5da86a14-a16c-4685-a82f-995d789f08f5
🧵 Thread below
Full analysis: https://helixbrief.com/article/5da86a14-a16c-4685-a82f-995d789f08f5
#MultipleMyeloma #CAR_T #Talquetamab #RRMM #Oncology #Hematology #CellTherapy #RealWorldEvidence #MyelomaResearch #Immunotherapy #GPRC5D #BCMA
August 2, 2025 at 11:00 PM
📊 Study Overview:
A multi-institutional retrospective analysis (20 centers: 18 US, 2 Germany) evaluated talquetamab, a GPRC5D-targeting bispecific antibody, as bridging therapy prior to CAR-T infusion in relapsed/refractory multiple myeloma (RRMM).
A multi-institutional retrospective analysis (20 centers: 18 US, 2 Germany) evaluated talquetamab, a GPRC5D-targeting bispecific antibody, as bridging therapy prior to CAR-T infusion in relapsed/refractory multiple myeloma (RRMM).
August 2, 2025 at 11:00 PM
📊 Study Overview:
A multi-institutional retrospective analysis (20 centers: 18 US, 2 Germany) evaluated talquetamab, a GPRC5D-targeting bispecific antibody, as bridging therapy prior to CAR-T infusion in relapsed/refractory multiple myeloma (RRMM).
A multi-institutional retrospective analysis (20 centers: 18 US, 2 Germany) evaluated talquetamab, a GPRC5D-targeting bispecific antibody, as bridging therapy prior to CAR-T infusion in relapsed/refractory multiple myeloma (RRMM).
💫 #ONCOnews💫
🚨BREAKING: FDA Grants Orphan Drug Designation to Sanofi’s SAR446523 for R/R MM!
🧬 SAR446523 is an ADCC-enhanced IgG1 monoclonal antibody targeting GPRC5D, a protein highly expressed on myeloma cells.
🔗 Read more: bit.ly/ONCOnews30JU-1
#OncoAlert #OncEd #MultipleMyeloma
🚨BREAKING: FDA Grants Orphan Drug Designation to Sanofi’s SAR446523 for R/R MM!
🧬 SAR446523 is an ADCC-enhanced IgG1 monoclonal antibody targeting GPRC5D, a protein highly expressed on myeloma cells.
🔗 Read more: bit.ly/ONCOnews30JU-1
#OncoAlert #OncEd #MultipleMyeloma
July 30, 2025 at 12:02 PM
💫 #ONCOnews💫
🚨BREAKING: FDA Grants Orphan Drug Designation to Sanofi’s SAR446523 for R/R MM!
🧬 SAR446523 is an ADCC-enhanced IgG1 monoclonal antibody targeting GPRC5D, a protein highly expressed on myeloma cells.
🔗 Read more: bit.ly/ONCOnews30JU-1
#OncoAlert #OncEd #MultipleMyeloma
🚨BREAKING: FDA Grants Orphan Drug Designation to Sanofi’s SAR446523 for R/R MM!
🧬 SAR446523 is an ADCC-enhanced IgG1 monoclonal antibody targeting GPRC5D, a protein highly expressed on myeloma cells.
🔗 Read more: bit.ly/ONCOnews30JU-1
#OncoAlert #OncEd #MultipleMyeloma
Sino Biopharma to acquire its Chinese peer LaNova Medicines, which previously secured licensing deals with #Merck (anti-VEGF x PD1 bispecific antibody in Ph1/2 in solid tumors) and #AstraZeneca (anti-GPRC5D ADC in Ph1/2 in r/r MM)
Total deal up to $951 million
www.fiercebiotech.com/biotech/sino...
Total deal up to $951 million
www.fiercebiotech.com/biotech/sino...
Sino Biopharm buys Merck's PD-1xVEGF bispecific partner LaNova for up to $951M
The PD-1xVEGF dealmaking wave that has captivated Western pharma companies is now surging within China. | Sino Biopharm said it will pay up to $951 million to acquire LaNova Medicines, which has ongoi...
www.fiercebiotech.com
July 17, 2025 at 3:37 PM
Sino Biopharma to acquire its Chinese peer LaNova Medicines, which previously secured licensing deals with #Merck (anti-VEGF x PD1 bispecific antibody in Ph1/2 in solid tumors) and #AstraZeneca (anti-GPRC5D ADC in Ph1/2 in r/r MM)
Total deal up to $951 million
www.fiercebiotech.com/biotech/sino...
Total deal up to $951 million
www.fiercebiotech.com/biotech/sino...
Silence of the myeloma clones: GPRC5D epigenetic regulation buff.ly/l8Xcld9 #hemesky
July 16, 2025 at 5:04 PM
Silence of the myeloma clones: GPRC5D epigenetic regulation buff.ly/l8Xcld9 #hemesky
Antigen-negative escape is a key driver of relapse after GPRC5D CAR T-cell therapy in MM.
buff.ly/pY5QoJL #hemesky
buff.ly/pY5QoJL #hemesky
July 11, 2025 at 6:02 PM
Antigen-negative escape is a key driver of relapse after GPRC5D CAR T-cell therapy in MM.
buff.ly/pY5QoJL #hemesky
buff.ly/pY5QoJL #hemesky
Thoughts on this? >> GPRC5D-directed Therapies Market is Anticipated to Gain
Momentum During the Forecast Period (2025-2034) Owing to Unmet Need
in Multiple Myeloma | DelveInsight >> Comment below! #AI #industry40 #IoT #healthtech #mhealth
Momentum During the Forecast Period (2025-2034) Owing to Unmet Need
in Multiple Myeloma | DelveInsight >> Comment below! #AI #industry40 #IoT #healthtech #mhealth
GPRC5D-directed Therapies Market is Anticipated to Gain
Momentum During the Forecast Period (2025-2034) Owing to Unmet Need
in Multiple Myeloma | DelveInsight
The GPRC5D-directed therapies market is witnessing robust growth, driven by the high unmet need in relapsed/refractory multiple myeloma. Innovative modalities like CAR-T cells, bispecific antibodies, and antibody-drug conjugates targeting GPRC5D are advancing rapidly through clinical pipelines. With limited cross-reactivity to normal tissues, GPRC5D presents a promising target, enhancing its commercial potential. LAS VEGAS, July 3, …
dlvr.it
July 3, 2025 at 10:27 PM
Thoughts on this? >> GPRC5D-directed Therapies Market is Anticipated to Gain
Momentum During the Forecast Period (2025-2034) Owing to Unmet Need
in Multiple Myeloma | DelveInsight >> Comment below! #AI #industry40 #IoT #healthtech #mhealth
Momentum During the Forecast Period (2025-2034) Owing to Unmet Need
in Multiple Myeloma | DelveInsight >> Comment below! #AI #industry40 #IoT #healthtech #mhealth
The Expanding Market of GPRC5D-directed Therapies for Multiple Myeloma by 2034#United_States#Las_Vegas#DelveInsight#GPRC5D#Myeloma
The Expanding Market of GPRC5D-directed Therapies for Multiple Myeloma by 2034
DelveInsight predicts significant growth in the GPRC5D-directed therapies market for relapsed multiple myeloma, driven by innovative treatments and rising demand.
third-news.com
July 3, 2025 at 9:38 PM
The Expanding Market of GPRC5D-directed Therapies for Multiple Myeloma by 2034#United_States#Las_Vegas#DelveInsight#GPRC5D#Myeloma
A next-generation bispecific antibody, JNJ-5322, targets both BCMA and GPRC5D to attack T-cells in relapsed/refractory #multiplemyeloma. Watch this video to learn about results from this phase 1 trial: https://mmsm.link/JN-5322
#mmsm
#mmsm
July 2, 2025 at 7:59 PM
A next-generation bispecific antibody, JNJ-5322, targets both BCMA and GPRC5D to attack T-cells in relapsed/refractory #multiplemyeloma. Watch this video to learn about results from this phase 1 trial: https://mmsm.link/JN-5322
#mmsm
#mmsm